Opening Plenary session

Welcome Introduction

·         Hervé de Kergrohen, Chairman, BioData

Official Opening Address

·         Carlo Lamprecht, Minister of Economy, State of Geneva

Key Note:

“Defining the future of Pharma-Biotech partnerships”

To fuel growth, pharmaceutical companies need to continually replenish their drug development pipelines. Innovative biotechnology companies need alliances and outsourcing agreements to validate their technologies and business models, generate revenues and foster growth. A natural fit — but what are the best partnership options for success in a global environment? What are the long-term solutions for building the successful alliances and partnerships of tomorrow?

·         Gilles Brisson, President of Management Board, Aventis

Panel Discussion:

“Will quality control in manufacturing processes and regulatory issues continue to impact market capitalization?”

Failure to meet existing or future regulatory standards and manufacturing requirements can have catastrophic effects on the valuation of a company. More than ever, successful pharma and biotech companies must devote increased resources to ensure regulatory compliance of drug products, their intermediates and the manufacturing process as well as to keep pace with emerging trends

in the quality control of production processes. The integration of new technologies in manufacturing may increase productivity but

more complexity may place larger demands on process management. What are the best solutions to improve quality control in an efficient manufacturing process?

Moderator:

·         Michel David, Vice President and General Manager, Clearant Europe

Panellists:

·         Jean-Yves le Cotonnec, Chief Executive Officer, Triskel

·         Philippe Le Goff, Dr. Ing., General Manager, H&LG Consultants SARL

·         David Sherwood, Vice President Quality Assurance, Lonza Biologics plc

·         Michel Venanzi, Fund Manager Life Sciences, Vice President, Lombard Odier Darier Hentsch & Cie

Company Presentations

• Group 1
• Group 2
• Group 3

Plenary session

Key Note:

“Will technological breakthroughs offset generic competition?”

It is estimated that over 10 billion USD in 2000 sales of biopharmaceuticals will come off patent over the next 5 years in the US alone. The availability of generics reduces drug prices and increases access to medicines. Some argue that it is also one of the most important elements in stimulating competition and innovation. In Europe, efforts to strengthen intellectual property status have not stimulated innovation over the past two decades when measured in terms of New Chemical Entities introduced.

In the United States, generic competition is fierce, investment in R&D is higher and the level of innovation is purportedly greater. Do these correlations extrapolate to the emerging biotechnology industry worldwide? Will the pace of technological breakthrough in the biotechnology sector be sufficient to offset increasing generic competition as biopharma increasingly makes the shift to protein-based drugs?

·         Simon Thompson, Group Director, Publications, IMS

Panel Discussion:

“Key success factors to increase R&D productivity”

The success rate for a drug candidate in clinical trials remains at the historical level of 1 in 10. At the same time, increasing competition and changing healthcare and regulatory environments mean that the biopharma industry must continually streamline and accelerate drug development. Over the past years, biopharma has invested heavily in new technologies including genomics, proteomics, bioinformatics, and high throughput screening methods. However, it remains to be seen which companies have most successfully integrated these new technologies into drug discovery and development. What are the preferred solutions to enhance speed to market, improve the return on investments in R&D, and manage the large amounts of data being generated by high throughput technologies? How can the industry make the R&D process more efficient and increase the number of drugs brought to the market?

Moderator:

·         Eric Halioua, Senior Manager, Arthur D. Little

Panellists:

·         Lionel Binns, Life Science Corporate Manager, Hewlett-Packard

·         Denis Hochstrasser, Head of the Department of Pathology, University Hospital of Geneva

·         Yigal Koltin, VP International R&D Alliance Development, Millennium Pharmaceuticals, Inc.

·         Emile Sutcliffe, President & Chief Executive Officer, Tecan

·         Lutz Weber, Chief Executive Officer, Morphochem

·         Barry Wilson, President, International, Senior Vice President, Medtronic

Company Presentations

• Group 3
• Group 4
• Group 5

17:00 - 19:00

Plenary Session

Key Note:

“Distinctive trends in the European Biotech industry - Can European markets foster a stronger Life Science industry?”

More than ever, the European Life Science industry needs to develop significant competitive advantages to deliver a stronger global presence. If it is to prosper, Europe still needs to rationalize its reimbursement processes, address country-specific pricing and regulatory issues and try to foster more effective pan-European R&D collaborations. With no near term recovery in the financial markets in sight, how can European companies improve R&D competitiveness and foster a stronger industry?

·         Tim Wells, Vice President Research, Head of Discovery, Serono

Panel Discussion:

“Which Biopharmaceutical companies to follow in 2003 and beyond?”

Across the industry, many life science companies have experienced dramatic turns in fortune over the past 12 months. The current market conditions may be restricting near-term growth of the industry. However, they also represent a unique opportunity for the discerning investor. Sound investment opportunity or quickly redundant technology? Which companies have the potential to become world leaders in their markets in 2003 and beyond?

Moderator:

·         Hervé de Kergrohen, Chairman, BioData

Panellists:

·         Laurence Cassarino, Equity Analyst-Pharmaceuticals, CDC IXIS Securities

·         Ivan Kugener, Senior Vice President, Deputy Director specialized Fund Management, Lombard Odier Darier Hentsch & Cie

·         Antoine Papiernik, General Partner, Sofinnova Partners

·         Sébastien Putallaz, Vice President, Global Biomedical Partners

·         Michael Sjöström, CFA, Founder and Chief Investment Officer, Sectoral Asset Management

Company Presentations

• Group 6
• Group 7
• Group 8

Company Presentations

• Group 9
• Group 10
• Group 11

Plenary session

Key Note:

“Presentation of BioAlps Initiatives”

·         Benoît Dubuis, Head of School of Life Sciences, EPFL

Panel Discussion:

“The role of public funding in the creation of start-up companies”

Most governments and other public-funded entities would embrace the concept that investment in health and medical research is an investment in the future well being of a nation. However, many have been slow to translate this awareness into supporting the creation of start-up companies in the healthcare industry. In some countries where public money has been forthcoming to entrepreneurs, the results have not always yielded tangible improvements. Lowering fiscal barriers, providing soft money inducements or introducing R&D tax credit schemes? What are the preferred options available to foster the development of early-stage companies? What should the role be, if any, of public funding in the creation and advancement of new enterprises in the life science industry?

Moderator:

·         Marc Schriber, President, Le Réseau

Panellists:

·         Xavier Comtesse, Deputy Director, Avenir Suisse

·         Arnd Kaltofen, Partner, VI Partners AG

·         Kotoku Kurachi, Director, Age Dimension Research Center, National Institute of Advanced Industrial Science and Technology (AIST)

·         Jesùs Martin-Garcia, Director, Geneva Biotech Incubator

·         Peter Reinisch, Partner, Global Life Science Ventures

·         Philippe Sordet, Chief of the Economic and Tourism Office of the State of Vaud